CaroSpir, approved by the Food and Drug Administration (FDA) in August 2017, is intended for adults who have difficulty swallowing or who cannot swallow tablets. Prior to the approval, patients had to obtain liquid spironolactone as a pharmacy compounded formulation, which commonly had limited shelf-life.
CaroSpir is approved to increase survival, manage edema, and to reduce hospitalization for heart failure (NYHA class III–IV) and reduced ejection fraction when used in addition to standard of therapy; for use as an add-on therapy for the treatment of hypertension, to lower blood pressure in adult patients who are not adequately controlled on other agents, as part of comprehensive cardiovascular risk management; and to manage edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restriction.
CaroSpir, a K+-sparing diuretic, acts primarily through competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. It causes increased amounts of sodium and water to be excreted, while retaining potassium.
CaroSpir is available as a banana-flavored 25mg/5mL strength oral suspension in 118mL and 473mL bottles.
For more information call (844) 321-1443 or visit CaroSpir.com.